Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: A mobile device includes a first display portion, a second display portion and a graphics processor. The first display portion is viewable while the second display portion is obscured when the mobile device is in a retracted configuration. Both display portions are viewable when the mobile device is in an expanded configuration. The graphics processor may be coupled to each display portion and configured to generate a first image for display on: the first display portion when the mobile device is in the retracted configuration; at least one of the display portions while the mobile device is in the expanded configuration; and at least one of the display portions while the mobile device transitions between the retracted configuration and the expanded configuration. The second display portion may be a flexible display material, such as an OLED display and with the first display portion may be a single sheet OLED display.

Abstract: The disclosure provides compositions, methods, and devices for use in delivering Mitomycin-C(MMC), an antineoplastic chemotherapy drug often used for bladder instillations to treat bladder cancer, which degrades in both acidic and alkaline environments. The disclosure provides a solution of buffered MMC (or a different drug) in 50% propylene glycol that maintains a pH from 7.0 to 8.0 when introduced into acidic solutions (pH of 5.0) and is stable when stored at 2-8° C. for greater than 134 days. This formulation can be produced in an FDA registered 503B Outsourcing facility in a pre-filled, ready-to-administer syringe kit with pre-attached closed system transfer device and accessories required for bladder instillation.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Abstract: A mobile device includes a first display portion, a second display portion and a graphics processor. The first display portion is viewable while the second display portion is obscured when the mobile device is in a retracted configuration. Both display portions are viewable when the mobile device is in an expanded configuration. The graphics processor may be coupled to each display portion and configured to generate a first image for display on: the first display portion when the mobile device is in the retracted configuration; at least one of the display portions while the mobile device is in the expanded configuration; and at least one of the display portions while the mobile device transitions between the retracted configuration and the expanded configuration. The second display portion may be a flexible display material, such as an OLED display and with the first display portion may be a single sheet OLED display.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: A mobile device includes a first display portion, a second display portion and a graphics processor. The first display portion is viewable while the second display portion is obscured when the mobile device is in a retracted configuration. Both display portions are viewable when the mobile device is in an expanded configuration. The graphics processor may be coupled to each display portion and configured to generate a first image for display on: the first display portion when the mobile device is in the retracted configuration; at least one of the display portions while the mobile device is in the expanded configuration; and at least one of the display portions while the mobile device transitions between the retracted configuration and the expanded configuration. The second display portion may be a flexible display material, such as an OLED display and with the first display portion may be a single sheet OLED display.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, Q, R3, R4, R5, R6, A1, and A2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

Abstract: Techniques are disclosed for capturing, transcoding, and caching off-air programming at a location local to the consumer. According to certain embodiments, a device is provided that receives off-air (e.g., broadcast) and/or cable (e.g., ClearQAM) programming via one or more antennas and caches the programming in various streams having various bit rates for later viewing using, for example, Adaptive Bit Rate (ABR) streaming. Such a device can be incorporated in a larger system that can stream content via a data communication network (e.g., the Internet) and the device in a seamless manner. The device also can be controlled by a remote system via the data communication network, and further can be configured to stream content to a remote device via the data communication network.

Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Abstract: Techniques are disclosed for capturing, transcoding, and caching off-air programming at a location local to the consumer. According to certain embodiments, a device is provided that receives off-air (e.g., broadcast) and/or cable (e.g., ClearQAM) programming via one or more antennas and caches the programming in various streams having various bit rates for later viewing using, for example, Adaptive Bit Rate (ABR) streaming. Such a device can be incorporated in a larger system that can stream content via a data communication network (e.g., the Internet) and the device in a seamless manner. The device also can be controlled by a remote system via the data communication network, and further can be configured to stream content to a remote device via the data communication network.

Abstract: Content receivers may simultaneously record multiple instances of content for multiple programming channels based on content provider instructions. Systems and methods utilize the content receivers to record these multiple instances from at least a single transponder. In some instances, multiple transponders may have a common control word so that content carried on each such transponder may be simultaneously received, decoded and recorded. Further, a single demodulator may be associated with multiple tuners, so that the single demodulator processes all content received from transponders with common control words and/or other encryption mechanisms.

Abstract: Techniques are disclosed for capturing, transcoding, and caching off-air programming at a location local to the consumer. According to certain embodiments, a device is provided that receives off-air (e.g., broadcast) and/or cable (e.g., ClearQAM) programming via one or more antennas and caches the programming in various streams having various bit rates for later viewing using, for example, Adaptive Bit Rate (ABR) streaming. Such a device can be incorporated in a larger system that can stream content via a data communication network (e.g., the Internet) and the device in a seamless manner. The device also can be controlled by a remote system via the data communication network, and further can be configured to stream content to a remote device via the data communication network.

Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.